Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effect of Lateral Versus Supine Positions on Postoperative Hypoxemia

NCT07545642 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-04-22
Last updated
2026-06-24

Condition(s) studied

Postoperative Hypoxemia

Investigational drug(s) / intervention(s)

Lateral decubitus position group (Group L)Supine position group (Group S)

Lateral decubitus position group (Group L): Upon admission to the Post-Anesthesia Care Unit (PACU), an independent researcher (attending anesthesiologist) assessed the patient using the Ramsay Sedation Scale (1: anxious and agitated; 2: awake, calm, and cooperative; 3: drowsy but responsive to verbal commands; 4: asleep but responsive to tactile stimulation or pain; 5: asleep with a sluggish response to stimulation; 6: deep sleep with no response). Patients in the Lateral Group (Group L) were maintained in the predetermined left lateral position. Standard monitoring was applied, and nasal cannula oxygen was administered at 2 L/min. If SpO₂ remained \>95% for at least 5 minutes, oxygen was discontinued for observation. To ensure strict adherence to the protocol, an independent researcher continuously monitored and verified patient positioning (corrections were made only if the patient rolled unconsciously). Patients were evaluated using the Aldrete discharge scoring system; discharge from the PACU occurred when a score of \>9 was a

Supine position group (Group S): Upon admission to the Post-Anesthesia Care Unit (PACU), an independent researcher (attending anesthesiologist) assessed the patient using the Ramsay Sedation Scale (1: anxious and agitated; 2: awake, calm, and cooperative; 3: drowsy but responsive to verbal commands; 4: asleep but responsive to tactile stimulation or pain; 5: asleep with a sluggish response to stimulation; 6: deep sleep with no response). Patients in the Supine Group (Group S) were turned from the predetermined lateral position to the supine position without a head pillow (head-of-bed elevation at 0 degrees). Standard monitoring was applied, and nasal cannula oxygen was administered at 2 L/min. If SpO₂ remained \>95% for at least 5 minutes, oxygen was discontinued for observation. To ensure strict adherence to the protocol, an independent researcher continuously monitored and verified patient positioning (corrections were made only if the patient rolled unconsciously). Patients were evaluated using the Aldrete discharge

Study summary

Using prospective real-world data, this study aims to determine whether the lateral decubitus position reduces the incidence of post-procedure hypoxemia in patients undergoing painless gastroscopy/colonoscopy, thereby providing a simple, non-invasive, and low-cost optimization strategy for clinical practice.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years. 2. Both sexes. 3. American Society of Anesthesiologists (ASA) physical status classification I-III. 4. Scheduled for combined painless esophagogastroduodenoscopy/colonoscopy or either of the two procedures. 5. Ability to understand the study protocol and provide written informed consent. 6. A broad set of inclusion criteria was adopted to enroll a patient population that better reflects routine clinical practice. The study aimed to enhance the generalizability of the findings by including patients with various comorbidities, such as preprocedural hypoxemia (room-air SpO₂ ≤ 90%), history of pulmonary surgery, obstructive sleep apnea (OSA), and other pulmonary conditions (including asthma, COPD, chronic bronchitis, emphysema, and pulmonary bullae). Exclusion Criteria: 1. Severe cardiovascular or cerebrovascular diseases. 2. Pregnant patients. 3. History of hypersensitivity to ciprofol. Withdrawal Criteria: 1. Endotracheal intubation required during the procedure. 2. Voluntary withdrawal requested by the patient or their legal representative.

Primary outcome measure(s)

  • Incidence of recovery-phase hypoxemia, — From PACU admission until discharge, assessed up to 30 minutes
    Proportion of participants experiencing hypoxemia (SpO₂ ≤ 90% lasting \>10 seconds) during the post-procedure recovery period.

Trial sites (1)

FacilityCityRegionStatus
General hospital of Ningxia medical university, Yinchuan, Ningxia Yinchuan Ningxia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07545642 on ClinicalTrials.gov ↗ ← All trials in China